TY - JOUR
T1 - The delayed effect of growth hormone on renal function in humans
AU - Hirschberg, R.
AU - Rabb, H.
AU - Bergamo, R.
AU - Kopple, J. D.
N1 - Funding Information:
This work was supported in part by the NIH Clinical Research Center Grant GCRC #RR 00425 and the UCLA CNRU grant #5 P01
Funding Information:
CA42710. Dr. Hirschberg was a recipient of a fellowship award of the Deutsche Forschungsgemeinschaft. The authors appreciate the skillful help of Harriet Tateyama, R.N., Merlyne Dubria, R.N., Connie So- riano, R.N., and the other members of the nursing and the Core Laboratory staff of the Clinical Research Center at Harbor-UCLA Medical Center. The somatrem used in this study was kindly donated by Barry Sherman, M.D., Genentech Inc., South San Francisco, California.
PY - 1989
Y1 - 1989
N2 - Growth hormone is reported to increase renal plasma flow (RPF) and glomerular filtration rate (GFR) in some but not all studies. The discrepant results could be due to a delay in the effects of growth hormone on renal function. We therefore examined whether a growth hormone injection does increase RPF and GFR, whether this increase is delayed, and whether elevation in RPF and GFR is associated with increased plasma levels of insulin-like growth factor I (IGF-I). Seven normal adults received a single intramuscular injection of growth hormone, 0.15 mg/kg, and serial PAH and inulin clearances were then monitored for 3 consecutive days. Plasma growth hormone levels peaked an average of 2.25 hours after injection, at 128 ± 12 SEM ng/ml, and then began to decrease; on the second day values were only slightly elevated and on the third day they were not different from baseline. Plasma IGF-I, analyzed by direct radioimmunoassay, did not change on the first day during 5.5 hours of measurements after injection. By the second day, plasma IGF-I was elevated to over twice baseline levels (P < 0.05) and remained elevated on the third day (P < 0.05). RPF and GFR did not change from baseline (546 ± 19 and 100 ± 3 ml/min/1.73 m2, respectively) during the 5.5 hours after injection on the first day. By the second day, RPF had risen to 715 ± 21, P < 0.05, and GFR to 130 ± 5 ml/min/1.73 m2, P < 0.05, and mean values remained elevated on the third day. The grand mean for total renal vascular resistance was decreased on the second and third days. Thus, after a growth hormone injection there was a rise in RPF and GFR which was delayed, was observed after plasma growth hormone levels had fallen to baseline, and which occurred in association with the increased plasma IGF-I levels. These findings suggest that growth hormone increases RPF and GFR indirectly through one or more mediators, one of which could be IGF-I.
AB - Growth hormone is reported to increase renal plasma flow (RPF) and glomerular filtration rate (GFR) in some but not all studies. The discrepant results could be due to a delay in the effects of growth hormone on renal function. We therefore examined whether a growth hormone injection does increase RPF and GFR, whether this increase is delayed, and whether elevation in RPF and GFR is associated with increased plasma levels of insulin-like growth factor I (IGF-I). Seven normal adults received a single intramuscular injection of growth hormone, 0.15 mg/kg, and serial PAH and inulin clearances were then monitored for 3 consecutive days. Plasma growth hormone levels peaked an average of 2.25 hours after injection, at 128 ± 12 SEM ng/ml, and then began to decrease; on the second day values were only slightly elevated and on the third day they were not different from baseline. Plasma IGF-I, analyzed by direct radioimmunoassay, did not change on the first day during 5.5 hours of measurements after injection. By the second day, plasma IGF-I was elevated to over twice baseline levels (P < 0.05) and remained elevated on the third day (P < 0.05). RPF and GFR did not change from baseline (546 ± 19 and 100 ± 3 ml/min/1.73 m2, respectively) during the 5.5 hours after injection on the first day. By the second day, RPF had risen to 715 ± 21, P < 0.05, and GFR to 130 ± 5 ml/min/1.73 m2, P < 0.05, and mean values remained elevated on the third day. The grand mean for total renal vascular resistance was decreased on the second and third days. Thus, after a growth hormone injection there was a rise in RPF and GFR which was delayed, was observed after plasma growth hormone levels had fallen to baseline, and which occurred in association with the increased plasma IGF-I levels. These findings suggest that growth hormone increases RPF and GFR indirectly through one or more mediators, one of which could be IGF-I.
UR - http://www.scopus.com/inward/record.url?scp=0024519592&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024519592&partnerID=8YFLogxK
U2 - 10.1038/ki.1989.65
DO - 10.1038/ki.1989.65
M3 - Article
C2 - 2709679
AN - SCOPUS:0024519592
SN - 0085-2538
VL - 35
SP - 865
EP - 870
JO - Kidney International
JF - Kidney International
IS - 3
ER -